Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for AstraZeneca Pharma India's EV-to-EBIT or its related term are showing as below:
NSE:ASTRAZEN'
s EV-to-EBIT Range Over the Past 10 Years
Min: 39.07 Med: 77.68 Max: 253.06
Current: 77.27
During the past 13 years, the highest EV-to-EBIT of AstraZeneca Pharma India was 253.06. The lowest was 39.07. And the median was 77.68.
NSE:ASTRAZEN's EV-to-EBIT is ranked worse than 92.63% of 692
companies
in the Drug Manufacturers industry
Industry Median: 15.73
vs NSE:ASTRAZEN: 77.27
AstraZeneca Pharma India (NSE:ASTRAZEN) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
AstraZeneca Pharma India's Enterprise Value for the quarter that ended in Mar. 2026 was ₹190,767 Mil.
AstraZeneca Pharma India's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,567 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India EV-to-EBIT Related Terms
AstraZeneca Pharma India EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's EV-to-EBIT falls into.
AstraZeneca Pharma India's current Enterprise Value is ₹198,367 Mil.
AstraZeneca Pharma India's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,567 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India (NSE:ASTRAZEN) has a EV-to-EBIT of 77.28 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AstraZeneca Pharma India and its competitors. This is near median its historical median of 77.68. Over the past decade, AstraZeneca Pharma India's EV-to-EBIT has ranged from 39.07 to 253.06. According to the industry distribution chart, AstraZeneca Pharma India ranks #641 out of 692 companies in the Drug Manufacturers industry, placing it in the top 92.6%.
Is AstraZeneca Pharma India's EV-to-EBIT too high?
AstraZeneca Pharma India's current EV-to-EBIT of 77.28 is near median its 10-year median of 77.68. Over the past 10 years, this metric has ranged from a low of 39.07 to a high of 253.06. The Drug Manufacturers industry median EV-to-EBIT is 15.73. AstraZeneca Pharma India's value of 77.28 is 391.3% above this industry median. Based on the distribution chart, AstraZeneca Pharma India ranks #641 out of 692 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AstraZeneca Pharma India has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #641 out of 692 companies for EV-to-EBIT. This places AstraZeneca Pharma India in the lower half of its industry. The industry median EV-to-EBIT is 15.73. AstraZeneca Pharma India's value of 77.28 is 391.3% above this benchmark. Historically, AstraZeneca Pharma India's own EV-to-EBIT has ranged from 39.07 to 253.06 over the past decade. While the company's 10-year median is 77.68 vs. the industry median of 15.73, AstraZeneca Pharma India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current EV-to-EBIT of 77.28 is 391.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current EV-to-EBIT is 77.28, which is near median its own 10-year median of 77.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹11,041.15, compared to a current price of ₹8,071.50 — trading 26.9% below its estimated fair value. The current EV-to-EBIT is 77.28, which is near median its 10-year median of 77.68 and 391.3% above the Drug Manufacturers industry median of 15.73. AstraZeneca Pharma India's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current EV-to-EBIT is 77.28 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹8,071.50 is trading 26.9% below its estimated GF Value™ of ₹11,041.15.
GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.
Key valuation signals for NSE:ASTRAZEN:
EV-to-EBIT: 77.28 (near median its 10-year median of 77.68)
GF Value™: ₹11,041.15 vs. price of ₹8,071.50 (26.9% below fair value)
Industry Position: 391.3% above the Drug Manufacturers median (#641 of 692)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
92GF Score
Get the complete analysis for NSE:ASTRAZEN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
